Suppr超能文献

使用具有降低细胞通透性的 Auristatin 衍生物抗体偶联物进行 HER2 肿瘤的精准放化疗。

Precision Chemoradiotherapy for HER2 Tumors Using Antibody Conjugates of an Auristatin Derivative with Reduced Cell Permeability.

机构信息

Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, California.

Department of Pathology, University of California San Diego, La Jolla, California.

出版信息

Mol Cancer Ther. 2020 Jan;19(1):157-167. doi: 10.1158/1535-7163.MCT-18-1302. Epub 2019 Oct 9.

Abstract

The most successful therapeutic strategies for locally advanced cancers continue to combine decades-old classical radiosensitizing chemotherapies with radiotherapy. Molecular targeted radiosensitizers offer the potential to improve the therapeutic ratio by increasing tumor-specific kill while minimizing drug delivery and toxicity to surrounding normal tissue. Auristatins are a potent class of anti-tubulins that sensitize cells to ionizing radiation damage and are chemically amenable to antibody conjugation. To achieve tumor-selective radiosensitization, we synthesized and tested anti-HER2 antibody-drug conjugates of two auristatin derivatives with ionizing radiation. Monomethyl auristatin E (MMAE) and monomethyl auristatin F (MMAF) were attached to the anti-HER2 antibodies trastuzumab and pertuzumab through a cleavable linker. While MMAE is cell permeable, MMAF has limited cell permeability as free drug resulting in diminished cytotoxicity and radiosensitization. However, when attached to trastuzumab or pertuzumab, MMAF was as efficacious as MMAE in blocking HER2-expressing tumor cells in G-M. Moreover, MMAF anti-HER2 conjugates selectively killed and radiosensitized HER2-rich tumor cells. Importantly, when conjugated to targeting antibody, MMAF had the advantage of decreased bystander and off-target effects compared with MMAE. In murine xenograft models, MMAF anti-HER2 antibody conjugates had less drug accumulated in the normal tissue surrounding tumors compared with MMAE. Therapeutically, systemically injected MMAF anti-HER2 conjugates combined with focal ionizing radiation increased tumor control and improved survival of mice with HER2-rich tumor xenografts. In summary, our results demonstrate the potential of cell-impermeable radiosensitizing warheads to improve the therapeutic ratio of radiotherapy by leveraging antibody-drug conjugate technology.

摘要

最成功的局部晚期癌症治疗策略仍然是将几十年前的经典放射增敏化疗与放射治疗相结合。分子靶向放射增敏剂有可能通过增加肿瘤特异性杀伤而最小化药物输送和对周围正常组织的毒性来提高治疗比率。auristatins 是一种有效的抗微管蛋白药物,可使细胞对电离辐射损伤敏感,并且在化学上适合与抗体偶联。为了实现肿瘤选择性放射增敏,我们合成并测试了两种 auristatin 衍生物与电离辐射的抗 HER2 抗体-药物偶联物。单甲基 auristatin E(MMAE)和单甲基 auristatin F(MMAF)通过可裂解接头连接到抗 HER2 抗体曲妥珠单抗和帕妥珠单抗上。虽然 MMAE 具有细胞渗透性,但 MMAF 作为游离药物具有有限的细胞渗透性,导致细胞毒性和放射增敏作用减弱。然而,当连接到曲妥珠单抗或帕妥珠单抗上时,MMAF 在阻止 G-M 中表达 HER2 的肿瘤细胞方面与 MMAE 一样有效。此外,MMAF 抗 HER2 缀合物选择性地杀死和放射增敏 HER2 丰富的肿瘤细胞。重要的是,与 MMAE 相比,当与靶向抗体偶联时,MMAF 具有减少旁观者和脱靶效应的优势。在小鼠异种移植模型中,与 MMAE 相比,MMAF 抗 HER2 抗体缀合物在肿瘤周围正常组织中积累的药物较少。在治疗方面,系统注射的 MMAF 抗 HER2 缀合物与焦点电离辐射相结合,增加了富含 HER2 的肿瘤异种移植小鼠的肿瘤控制并提高了生存率。总之,我们的结果表明,细胞不可渗透的放射增敏弹头通过利用抗体-药物偶联物技术有可能提高放射治疗的治疗比率。

相似文献

1
Precision Chemoradiotherapy for HER2 Tumors Using Antibody Conjugates of an Auristatin Derivative with Reduced Cell Permeability.
Mol Cancer Ther. 2020 Jan;19(1):157-167. doi: 10.1158/1535-7163.MCT-18-1302. Epub 2019 Oct 9.
2
HER2-targeted antibody drug conjugates for ovarian cancer therapy.
Eur J Pharm Sci. 2016 Oct 10;93:274-86. doi: 10.1016/j.ejps.2016.08.015. Epub 2016 Aug 7.
3
A Conjugate Based on Anti-HER2 Diaffibody and Auristatin E Targets HER2-Positive Cancer Cells.
Int J Mol Sci. 2017 Feb 14;18(2):401. doi: 10.3390/ijms18020401.
5
Tumor radiosensitization by monomethyl auristatin E: mechanism of action and targeted delivery.
Cancer Res. 2015 Apr 1;75(7):1376-1387. doi: 10.1158/0008-5472.CAN-14-1931. Epub 2015 Feb 13.
6
Development and biological assessment of MMAE-trastuzumab antibody-drug conjugates (ADCs).
Breast Cancer. 2021 Jan;28(1):216-225. doi: 10.1007/s12282-020-01153-5. Epub 2020 Sep 5.
7
Novel Auristatins with High Bystander and Cytotoxic Activities in Drug Efflux-positive Tumor Models.
Mol Cancer Ther. 2021 Feb;20(2):320-328. doi: 10.1158/1535-7163.MCT-20-0618. Epub 2020 Dec 7.
8
A novel humanized anti-HER2 antibody conjugated with MMAE exerts potent anti-tumor activity.
Breast Cancer Res Treat. 2015 Aug;153(1):123-33. doi: 10.1007/s10549-015-3503-3. Epub 2015 Aug 8.
10
An anti-HER2 antibody conjugated with monomethyl auristatin E is highly effective in HER2-positive human gastric cancer.
Cancer Biol Ther. 2016 Apr 2;17(4):346-54. doi: 10.1080/15384047.2016.1139248. Epub 2016 Feb 6.

引用本文的文献

2
Advances in Trop-2 targeted antibody-drug conjugates for breast cancer: mechanisms, clinical applications, and future directions.
Front Immunol. 2024 Nov 1;15:1495675. doi: 10.3389/fimmu.2024.1495675. eCollection 2024.
3
Drug conjugates for the treatment of lung cancer: from drug discovery to clinical practice.
Exp Hematol Oncol. 2024 Mar 1;13(1):26. doi: 10.1186/s40164-024-00493-8.
4
The promise and challenges of combination therapies with antibody-drug conjugates in solid tumors.
J Hematol Oncol. 2024 Jan 4;17(1):1. doi: 10.1186/s13045-023-01509-2.
6
The cell-line-derived subcutaneous tumor model in preclinical cancer research.
Nat Protoc. 2022 Sep;17(9):2108-2128. doi: 10.1038/s41596-022-00709-3. Epub 2022 Jul 20.
8
Exploiting Radiation Induction of Antigens in Cancer: Targeted Drug Delivery.
Int J Mol Sci. 2022 Mar 11;23(6):3041. doi: 10.3390/ijms23063041.
9
Targeted Chemoradiotherapy of Prostate Cancer Using Gold Nanoclusters with Protease Activatable Monomethyl Auristatin E.
ACS Appl Mater Interfaces. 2022 Apr 6;14(13):14916-14927. doi: 10.1021/acsami.1c23780. Epub 2022 Mar 22.
10
CD19-Targeted Immunotherapies for Diffuse Large B-Cell Lymphoma.
Front Immunol. 2022 Feb 24;13:837457. doi: 10.3389/fimmu.2022.837457. eCollection 2022.

本文引用的文献

1
CRISPR-Cas9 screens identify regulators of antibody-drug conjugate toxicity.
Nat Chem Biol. 2019 Oct;15(10):949-958. doi: 10.1038/s41589-019-0342-2. Epub 2019 Aug 26.
3
An auristatin-based antibody-drug conjugate targeting HER3 enhances the radiation response in pancreatic cancer.
Int J Cancer. 2019 Oct 1;145(7):1838-1851. doi: 10.1002/ijc.32273. Epub 2019 Apr 1.
6
Resistance to Antibody-Drug Conjugates.
Cancer Res. 2018 May 1;78(9):2159-2165. doi: 10.1158/0008-5472.CAN-17-3671. Epub 2018 Apr 13.
7
Antibody-Drug Conjugates for Cancer Treatment.
Annu Rev Med. 2018 Jan 29;69:191-207. doi: 10.1146/annurev-med-061516-121357.
8
Near Complete Response in a Patient with Classical Hodgkin Lymphoma Treated with Brentuximab Vedotin Concurrent with Radiation Therapy.
Case Rep Oncol. 2017 Sep 6;10(3):795-801. doi: 10.1159/000479224. eCollection 2017 Sep-Dec.
9

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验